Scout-Dose-TCM: Direct and Prospective Scout-Based Estimation of Personalized Organ Doses from Tube Current Modulated CT Exams

TL;DR

This paper introduces Scout-Dose-TCM, a deep learning model that provides real-time, personalized organ dose estimates from tube current modulated CT scans, outperforming traditional methods and eliminating the need for organ segmentation during inference.

Contribution

The study presents a novel deep learning approach that directly estimates organ doses from scout images, improving accuracy and efficiency over existing size-specific dose estimation methods.

Findings

Scout-Dose-TCM achieved 7% average absolute percentage error.

It significantly outperformed Global CTDIvol in dose estimation accuracy.

The model provided strong correlation with Monte Carlo benchmarks.

Abstract

This study proposes Scout-Dose-TCM for direct, prospective estimation of organ-level doses under tube current modulation (TCM) and compares its performance to two established methods. We analyzed contrast-enhanced chest-abdomen-pelvis CT scans from 130 adults (120 kVp, TCM). Reference doses for six organs (lungs, kidneys, liver, pancreas, bladder, spleen) were calculated using MC-GPU and TotalSegmentator. Based on these, we trained Scout-Dose-TCM, a deep learning model that predicts organ doses corresponding to discrete cosine transform (DCT) basis functions, enabling real-time estimates for any TCM profile. The model combines a feature learning module that extracts contextual information from lateral and frontal scouts and scan range with a dose learning module that output DCT-based dose estimates. A customized loss function incorporated the DCT formulation during training. For comparison, we implemented size-specific dose estimation per AAPM TG 204 (Global CTDIvol) and its organ-level TCM-adapted version (Organ CTDIvol). A 5-fold cross-validation assessed generalizability by comparing mean absolute percentage dose errors and r-squared correlations with benchmark doses. Average absolute percentage errors were 13% (Global CTDIvol), 9% (Organ CTDIvol), and 7% (Scout-Dose-TCM), with bladder showing the largest discrepancies (15%, 13%, and 9%). Statistical tests confirmed Scout-Dose-TCM significantly reduced errors vs. Global CTDIvol across most organs and improved over Organ CTDIvol for the liver, bladder, and pancreas. It also achieved higher r-squared values, indicating stronger agreement with Monte Carlo benchmarks. Scout-Dose-TCM outperformed Global CTDIvol and was comparable to or better than Organ CTDIvol, without requiring organ segmentations at inference, demonstrating its promise as a tool for prospective organ-level dose estimation in CT.